Compounded GLP-1 medications have made weight loss treatment accessible to millions of people who couldn't afford brand-name drugs. Monthly costs of $150–$400 versus $1,000+ created a genuine pathway for patients who would otherwise have no option. But in 2026, the regulatory environment around compounded GLP-1s is tightening — and the safety question is more relevant than ever.
What Are Compounded GLP-1s?
Compounded medications are custom-prepared versions of drugs made by compounding pharmacies. Unlike FDA-approved brand-name medications, compounded drugs are not reviewed by the FDA for safety, efficacy, or manufacturing consistency. They're legal under specific conditions — primarily when there's a documented drug shortage or when a patient has a medical need that can't be met by a commercially available product.
During the semaglutide and tirzepatide shortages of 2023–2025, compounding pharmacies were legally permitted to produce copies of these drugs. Millions of patients accessed compounded semaglutide through telehealth providers at a fraction of brand-name cost.
The Shortage Is Over — What Now?
The FDA resolved the semaglutide shortage designation in February 2025 and the tirzepatide shortage in October 2024. Once a shortage ends, compounding pharmacies can no longer produce "essentially a copy" of the brand-name product for routine dispensing. However, 503A pharmacies may still legally compound GLP-1 formulations that are meaningfully different — alternative doses, different formulations (sublingual, oral), or combinations with additional ingredients like B12 or L-carnitine — as long as they have a valid patient-specific prescription.
The FDA has been aggressive in enforcement. On March 3, 2026, the agency issued 30 warning letters to telehealth companies, citing misbranding, unsubstantiated claims, and distribution of unapproved drug products. Several companies named — including MEDVi, which received a separate February 2026 warning — continue to operate but face increased scrutiny.
Are Compounded GLP-1s Safe?
The safety of compounded GLP-1s depends entirely on the pharmacy producing them. Well-run, accredited compounding pharmacies (look for PCAB accreditation or state board of pharmacy compliance) can produce high-quality medications. But there's significant variability across the industry.
Specific concerns include potency inconsistency (the actual dose may differ from what's labeled), sterility issues (particularly for injectable formulations), lack of stability testing (how well the drug holds up over time), and the absence of the rigorous clinical trial data that FDA-approved drugs undergo.
How to Evaluate a Compounding Pharmacy
If you're using compounded GLP-1 medications, verify that the pharmacy holds a current state license, ask whether they have PCAB (Pharmacy Compounding Accreditation Board) accreditation, confirm they perform third-party potency and sterility testing, check whether the pharmacy has received any FDA warning letters (searchable on FDA.gov), and ensure your prescription was written by a licensed provider who has evaluated your medical history.
The Bottom Line
Compounded GLP-1s have helped millions of people access weight loss treatment they couldn't otherwise afford. That's a genuine and important public health benefit. But as brand-name options get cheaper — Foundayo starts at $149/month, the Wegovy pill at $149 for starting doses — the cost gap is narrowing.
If you're currently on a compounded GLP-1, talk to your prescriber about whether FDA-approved options are now accessible for you. If compounded remains your best path, vet your pharmacy carefully.